Phase I Multidose-Escalation Study of the Anti-Cd19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma

Journal of Clinical Oncology - United States
doi 10.1200/jco.2011.39.4403
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or With Dexamethasone in Relapsed and Refractory Multiple Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2010English

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Phase I Dose-Escalation Study of Intravenous Panobinostat in Patients With Lymphoma and Solid Tumors

Investigational New Drugs
OncologyPharmacology
2013English

Third-Generation Anti-Cd19 Chimeric Antigen Receptor T-Cells Incorporating a TLR2 Domain for Relapsed or Refractory B-Cell Lymphoma: A Phase I Clinical Trial Protocol (ENABLE)

BMJ Open
Medicine
2020English

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

Phase I Study of Romidepsin and Liposomal Doxorubicin in Relapsed or Refractory T-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Intravenous Immunoglobulin Therapy Use in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated With Tisagenlecleucel in the Juliet Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Anti-Cd19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy